Abstract：Objective To investigate the clinical effect of hepatic arterial chemoembolization in the treatment of primary liver cancer.Methods A total of 100 patients with primary liver cancer who were admitted to our hospital from January 2010 to May 2014 were selected as the study subjects and randomly divided into observation group and control group,50 patients in each group.The patients in the observation group were treated with hepatic arterial chemoembolization for clinical treatment.The patients in the control group were treated with supportive therapy for clinical treatment.After the end of treatment,the clinical efficacy,progression-free survival(PFS),overall surviva(OS),and incidence rate of adverse reactions were observed and recorded in both groups,and comparative analysis was carried out.Results There was no significant difference in objective remission rate and disease control rate between the two groups(P＞0.05);the mean values of PFS and OS in the observation group was(11.25±0.84)months and(18.57±0.99)months respectively.The control group was(7.51±0.67)months and(17.03±0.89)months respectively.The comparative analysis showed that the observation group was significantly higher than that in the control group in terms of the mean value of PFS(P＜0.05).However,there was no significant difference in the mean value of OS(P＞0.05);both groups showed different degrees of adverse reactions.The incidence rate of nausea and vomiting was higher in the observation group than that in the control group(P＜0.05);all adverse reactions were relieved or disappeared after symptomatic treatment,and there was no serious effects on the treatment for patients.Conclusion Hepatic arterial chemoembolization has a significant therapeutic effect in the treatment of primary liver cancer.The treatment method can effectively improve the patient′s survival status,increase the patient′s survival time and survival rate,so it is worthy of learning and promotion in the clinical practice.
京公网安备 11010502046607号